Table 2.
Relationship of TSP and TLS with clinicopathological characteristics of nmCRC patients in the training set.
| Characteristics | Training set (n=114) n (%) | ||||
|---|---|---|---|---|---|
| P-TLS density (median) | P value | H-TSP | L-TSP | P value | |
| Sex | 0.6679 | 0.7030 | |||
| Male | 0.1660 (0.0815, 0.2745) | 28 (59.6) | 37 (55.2) | ||
| Female | 0.1340 (0.0905, 0.2410) | 19 (40.4) | 30 (44.8) | ||
| Age | 0.1484 | 0.6953 | |||
| >60 | 0.1340 (0.0710, 0.2380) | 18 (38.3) | 23 (34.3) | ||
| ≤60 | 0.1860 (0.0880, 0.2605) | 29 (61.7) | 44 (65.7) | ||
| Location | 0.8294 | 0.6595 | |||
| Rectum | 0.1370 (0.0810, 0.2480) | 30 (63.8) | 45 (67.2) | ||
| Left colon | 0.1630 (0.1010, 0.3320) | 7 (14.9) | 12 (17.9) | ||
| Right colon | 0.1680 (0.0980, 0.2480) | 10 (21.3) | 10 (14.9) | ||
| Lymph node-positive | 0.2305 | 0.0002 | |||
| YES | 0.1470 (0.0710, 0.2250) | 29 (61.7) | 18 (26.9) | ||
| NO | 0.1640 (0.0880, 0.3010) | 18 (38.3) | 49 (73.1) | ||
| Perineural invasion | 0.0947 | 0.4868 | |||
| YES | 0.1170 (0.0710, 0.1860) | 11 (23.4) | 12 (17.9) | ||
| NO | 0.1660 (0.0880, 0.2640) | 36 (76.6) | 55 (82.1) | ||
| Vascular invasion | 0.0035 | 0.0022 | |||
| YES | 0.0880 (0.0470, 0.1560) | 14 (29.8) | 5 (7.5) | ||
| NO | 0.1710 (0.0900, 0.2640) | 33 (70.2) | 62 (92.5) | ||
| T stage | 0.2449 | 0.0384 | |||
| T1 | 0.1420 (0.0700, 0.3010) | 1 (2.1) | 6 (9.0) | ||
| T2 | 0.1260 (0.0870, 0.2310) | 4 (8.5) | 11 (16.4) | ||
| T3 | 0.1700 (0.0950, 0.2640) | 35 (74.5) | 48 (71.6) | ||
| T4 | 0.0880 (0.0450, 0.1795) | 7 (14.9) | 2 (3.0) | ||
| N stage | 0.4319 | 0.0009 | |||
| N0 | 0.1640 (0.0880, 0.3010) | 18 (38.3) | 49 (73.1) | ||
| N1 | 0.1420 (0.0673, 0.2308) | 18 (38.3) | 12 (17.9) | ||
| N2 | 0.1510 (0.0650, 0.2205) | 11 (23.4) | 6 (9.0) | ||
| TNM stage* | 0.2571 | 0.0009 | |||
| I | 0.1340 (0.0853, 0.2465) | 5 (10.6) | 17 (25.4) | ||
| II | 0.1990 (0.0970, 0.3270) | 13 (27.7) | 32 (47.8) | ||
| III | 0.1470 (0.0710, 0.2250) | 29 (61.7) | 18 (26.9) | ||
| Tumor grade | 0.2099 | 0.6992 | |||
| G1 | 0.1250 (0.0710, 0.2140) | 12 (25.5) | 15 (22.4) | ||
| G2 | 0.1465 (0.0870, 0.2693) | 31 (66.0) | 43 (64.2) | ||
| G3 | 0.2030 (0.1340, 0.3185) | 4 (8.5) | 9 (13.4) | ||
| MMR | 0.0003 | 0.7902 | |||
| dMMR | 0.3530 (0.1520, 0.4325) | 6 (12.8) | 11 (16.4) | ||
| pMMR | 0.1370 (0.0780, 0.2320) | 41 (87.2) | 56 (83.6) | ||
| TSP | 0.0205 | - | - | - | |
| H-TSP | 0.1130 (0.0540, 0.2380) | - | - | ||
| L-TSP | 0.1710 (0.1060, 0.2910) | - | - | ||
| Presence of In-TLS | - | 0.1953 | |||
| Yes | - | 9 (19.1) | 21 (31.3) | ||
| No | - | 38 (80.9) | 46 (68.7) | ||
| In-TLS density | - | - | 0.0064 | 0.0122 | 0.1568 |
P-TLS, peritumoral tertiary lymphoid structure; In-TLS, intratumoral TLS; TSP, tumor stroma percentage; H-TSP, high TSP; L-TSP, low TSP; nmCRC, non-metastatic colorectal cancer; MMR, mismatch repair. *The 8th AJCC TNM staging system. The bold valuse was considered as statistically significant difference.